SeaDragon – Market Update

NZX / MEDIA RELEASE 26 April 2016. Link here. Omega-3 update; Omega-2 sales slow; Revised financial guidance SeaDragon Limited (NZX:SEA) is pleased to update the market on the following recent events. Omega-3 Refinery As previously noted to the market, the commissioning of SeaDragon’s new Omega-3 refinery has been successfully completed, with the plant meeting performance […]

AVH – ReGenerCell Skin Regeneration Technology Decreases Size and Pain in Chronic Wounds

Chronic Wounds Data Presented at Skin Regeneration Symposium in Cambridge, UK. Cambridge, United Kingdom, 20 April 2016. Link here.

AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort

SAN DIEGO, April 20, 2016– Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today provided an update on the progress of its ongoing first-in-man Phase I clinical trial for chronic rhinosinusitis patients treated with AmpliPhi’s proprietary phage cocktail AB-SA01. The first cohort, […]

Skin Regeneration Technology Critical to Recovery and Quality of Life in Burns Patients Say Top Clinicians

Extensive burns research data presented at Skin Regeneration Symposium in Cambridge, UK. – ReCell technology improves burn wound healing, reduces scarring, discoloration and itching – ReCell effective for extreme burns in emergency situations – 95% healing in less than 2 months achieved with ReCell for explosion patient with 70% burn – Leading EU hospital incorporating […]

AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon

SAN DIEGO, April 14, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to Intrexon to cancel the Exclusive Channel Collaboration (ECC) with Intrexon. Under the terms of the agreement, AmpliPhi has the […]

AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

SAN DIEGO, April 12, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix […]